NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis

Interventions: Kesimpta

Countries: Japan

This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.

Eligibility overview

Sex: ALL

Age: 0 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta
2. Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients

   * Relapsing-remitting MS
   * Active SPMS

Exclusion Criteria:

1. Patients with a history of treatment with a drug containing the same ingredient as Kesimpta (investigational drug or post-marketing clinical study drug)
2. Patients with a history of hypersensitivity to any of the Kesimpta ingredients

Locations (103)

Ichinomiya, Aichi-ken, Japan
Nagakute, Aichi-ken, Japan
Nagoya, Aichi-ken, Japan
Nagoya, Aichi-ken, Japan
Nagoya, Aichi-ken, Japan
Tokoname, Aichi-ken, Japan
Toyohashi, Aichi-ken, Japan
Hachinohe, Aomori, Japan
Hachinohe, Aomori, Japan
Hirosaki, Aomori, Japan
Chiba, Chiba, Japan
Ichikawa, Chiba, Japan
Narita, Chiba, Japan
Yachiyo, Chiba, Japan
Tōon, Ehime, Japan
Fukuoka, Fukuoka, Japan
Iizuka, Fukuoka, Japan
Kitakyushu, Fukuoka, Japan
Kurume, Fukuoka, Japan
Omuta, Fukuoka, Japan
Gifu, Gifu, Japan
Maebashi, Gunma, Japan
Maebashi, Gunma, Japan
Fukuyama, Hiroshima, Japan
Asahikawa, Hokkaido, Japan
Hakodate, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
Sapporo, Hokkaido, Japan
+ 73 more on CT.gov